The in vivo efficacy of ATO was demonstrated in both studies; it inhibited the growth of Ptch+/−; p53−/− medulloblastoma allografts and Ewing sarcoma xenografts and increased survival of constitutively activated SMO transgenic mice with MB [134,135]. This evidence concerns the gene TP53 and medulloblastoma.